Skip to main content
PMC home page
Journal of Neurology, Neurosurgery, and Psychiatry logoLink to Journal of Neurology, Neurosurgery, and Psychiatry
. 2000 Apr;68(4):472–478. doi: 10.1136/jnnp.68.4.472

Myopathy with anti-Jo-1 antibodies: pathology in perimysium and neighbouring muscle fibres

T Mozaffar 1, A Pestronk 1
PMCID: PMC1736872  PMID: 10727483

Abstract

OBJECTIVE—To evaluate muscle pathology and clinical characteristics in patients with a myopathy and serum antibodies to the Jo-1 antigen (histidyl t-RNA synthetase).
BACKGROUND—Anti-Jo-1 antibodies occur in syndromes that may include muscle weakness and pain, Raynaud's phenomenon, interstitial lung disease, arthritis, and a skin rash different from that seen in dermatomyositis. The muscle pathology is not well defined.
METHODS—Case series. Review of charts, muscle biopsies, and laboratory records. Features of myopathology in 11 patients with anti-Jo-1 antibody associated myopathies were compared with other types of inflammatory myopathies.
RESULTS—Myopathology in patients with anti-Jo-1 antibodies consistently included fragmentation of, and macrophage predominant inflammation in, perimysial connective tissue. Perifascicular myopathic changes, including atrophy, regenerating muscle fibres, and some muscle fibre necrosis, were most common in regions near the connective tissue pathology and were most prominent in patients with more severe weakness. Unlike many other inflammatory myopathies, inflammation in endomysial and perivascular regions was uncommon. By contrast with dermatomyositis, capillary density was normal.
CONCLUSIONS—Myopathological changes in the anti-Jo-1 antibody syndrome include perimysial connective tissue fragmentation and inflammation, with muscle fibre pathology in neighbouring perifascicular regions. Myositis with anti-Jo-1 antibodies may result from an immune mediated disorder of connective tissue.



Full Text

The Full Text of this article is available as a PDF (247.4 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Arahata K., Engel A. G. Monoclonal antibody analysis of mononuclear cells in myopathies. IV: Cell-mediated cytotoxicity and muscle fiber necrosis. Ann Neurol. 1988 Feb;23(2):168–173. doi: 10.1002/ana.410230210. [DOI] [PubMed] [Google Scholar]
  2. Arnett F. C., Hirsch T. J., Bias W. B., Nishikai M., Reichlin M. The Jo-1 antibody system in myositis: relationships to clinical features and HLA. J Rheumatol. 1981 Nov-Dec;8(6):925–930. [PubMed] [Google Scholar]
  3. Bernstein R. M., Morgan S. H., Chapman J., Bunn C. C., Mathews M. B., Turner-Warwick M., Hughes G. R. Anti-Jo-1 antibody: a marker for myositis with interstitial lung disease. Br Med J (Clin Res Ed) 1984 Jul 21;289(6438):151–152. doi: 10.1136/bmj.289.6438.151. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Blume G., Pestronk A., Frank B., Johns D. R. Polymyositis with cytochrome oxidase negative muscle fibres. Early quadriceps weakness and poor response to immunosuppressive therapy. Brain. 1997 Jan;120(Pt 1):39–45. doi: 10.1093/brain/120.1.39. [DOI] [PubMed] [Google Scholar]
  5. Bohan A., Peter J. B., Bowman R. L., Pearson C. M. Computer-assisted analysis of 153 patients with polymyositis and dermatomyositis. Medicine (Baltimore) 1977 Jul;56(4):255–286. doi: 10.1097/00005792-197707000-00001. [DOI] [PubMed] [Google Scholar]
  6. Cohen M. G., Ho K. K., Webb J. Finger joint calcinosis followed by osteolysis in a patient with multisystem connective tissue disease and anti-Jo-1 antibody. J Rheumatol. 1987 Jun;14(3):605–608. [PubMed] [Google Scholar]
  7. Dalakas M. C. Polymyositis, dermatomyositis and inclusion-body myositis. N Engl J Med. 1991 Nov 21;325(21):1487–1498. doi: 10.1056/NEJM199111213252107. [DOI] [PubMed] [Google Scholar]
  8. Dawson J. K., Abernethy V. E., Lynch M. P. Effective treatment of anti Jo-1 antibody-positive polymyositis with cyclosporin. Br J Rheumatol. 1997 Jan;36(1):144–145. doi: 10.1093/rheumatology/36.1.144. [DOI] [PubMed] [Google Scholar]
  9. Emslie-Smith A. M., Engel A. G. Microvascular changes in early and advanced dermatomyositis: a quantitative study. Ann Neurol. 1990 Apr;27(4):343–356. doi: 10.1002/ana.410270402. [DOI] [PubMed] [Google Scholar]
  10. Engel A. G., Arahata K., Emslie-Smith A. Immune effector mechanisms in inflammatory myopathies. Res Publ Assoc Res Nerv Ment Dis. 1990;68:141–157. [PubMed] [Google Scholar]
  11. Friedman A. W., Targoff I. N., Arnett F. C. Interstitial lung disease with autoantibodies against aminoacyl-tRNA synthetases in the absence of clinically apparent myositis. Semin Arthritis Rheum. 1996 Aug;26(1):459–467. doi: 10.1016/s0049-0172(96)80026-6. [DOI] [PubMed] [Google Scholar]
  12. Griggs R. C., Askanas V., DiMauro S., Engel A., Karpati G., Mendell J. R., Rowland L. P. Inclusion body myositis and myopathies. Ann Neurol. 1995 Nov;38(5):705–713. doi: 10.1002/ana.410380504. [DOI] [PubMed] [Google Scholar]
  13. Jenkins E. A., Hull R. G., Thomas A. L. D-penicillamine and polymyositis: the significance of the anti-Jo-1 antibody. Br J Rheumatol. 1993 Dec;32(12):1109–1110. doi: 10.1093/rheumatology/32.12.1109. [DOI] [PubMed] [Google Scholar]
  14. Kissel J. T., Mendell J. R., Rammohan K. W. Microvascular deposition of complement membrane attack complex in dermatomyositis. N Engl J Med. 1986 Feb 6;314(6):329–334. doi: 10.1056/NEJM198602063140601. [DOI] [PubMed] [Google Scholar]
  15. Love L. A., Leff R. L., Fraser D. D., Targoff I. N., Dalakas M., Plotz P. H., Miller F. W. A new approach to the classification of idiopathic inflammatory myopathy: myositis-specific autoantibodies define useful homogeneous patient groups. Medicine (Baltimore) 1991 Nov;70(6):360–374. doi: 10.1097/00005792-199111000-00002. [DOI] [PubMed] [Google Scholar]
  16. Mathews M. B., Bernstein R. M. Myositis autoantibody inhibits histidyl-tRNA synthetase: a model for autoimmunity. Nature. 1983 Jul 14;304(5922):177–179. doi: 10.1038/304177a0. [DOI] [PubMed] [Google Scholar]
  17. Mitra D., Lovell C. L., Macleod T. I., Tan R. S., Maddison P. J. Clinical and histological features of 'mechanic's hands' in a patient with antibodies to Jo-1--a case report. Clin Exp Dermatol. 1994 Mar;19(2):146–148. doi: 10.1111/j.1365-2230.1994.tb01144.x. [DOI] [PubMed] [Google Scholar]
  18. Nishikai M., Reichlin M. Heterogeneity of precipitating antibodies in polymyositis and dermatomyositis. Characterization of the Jo-1 antibody system. Arthritis Rheum. 1980 Aug;23(8):881–888. doi: 10.1002/art.1780230802. [DOI] [PubMed] [Google Scholar]
  19. Oddis C. V., Medsger T. A., Jr, Cooperstein L. A. A subluxing arthropathy associated with the anti-Jo-1 antibody in polymyositis/dermatomyositis. Arthritis Rheum. 1990 Nov;33(11):1640–1645. doi: 10.1002/art.1780331106. [DOI] [PubMed] [Google Scholar]
  20. Rider L. G., Miller F. W., Targoff I. N., Sherry D. D., Samayoa E., Lindahl M., Wener M. H., Pachman L. M., Plotz P. H. A broadened spectrum of juvenile myositis. Myositis-specific autoantibodies in children. Arthritis Rheum. 1994 Oct;37(10):1534–1538. doi: 10.1002/art.1780371019. [DOI] [PubMed] [Google Scholar]
  21. Ringel S. P., Carry M. R., Aguilera A. J., Starcevich J. M. Quantitative histopathology of the inflammatory myopathies. Arch Neurol. 1986 Oct;43(10):1004–1009. doi: 10.1001/archneur.1986.00520100026010. [DOI] [PubMed] [Google Scholar]
  22. Ringel S. P., Forstot J. Z., Tan E. M., Wehling C., Griggs R. C., Butcher D. Sjögren's syndrome and polymyositis or dermatomyositis. Arch Neurol. 1982 Mar;39(3):157–163. doi: 10.1001/archneur.1982.00510150027007. [DOI] [PubMed] [Google Scholar]
  23. Shi M. H., Tsui F. W., Rubin L. A. Cellular localization of the target structures recognized by the anti-Jo-1 antibody: immunofluorescence studies on cultured human myoblasts. J Rheumatol. 1991 Feb;18(2):252–258. [PubMed] [Google Scholar]
  24. Simon D. B., Ringel S. P., Sufit R. L. Clinical spectrum of fascial inflammation. Muscle Nerve. 1982 Sep;5(7):525–537. doi: 10.1002/mus.880050707. [DOI] [PubMed] [Google Scholar]
  25. Targoff I. N., Reichlin M. Measurement of antibody to Jo-1 by ELISA and comparison to enzyme inhibitory activity. J Immunol. 1987 May 1;138(9):2874–2882. [PubMed] [Google Scholar]
  26. Yang D. C., Dang C. V., Arnett F. C. Rat liver histidyl-tRNA synthetase. Purification and inhibition by the myositis-specific anti-Jo-1 autoantibody. Biochem Biophys Res Commun. 1984 Apr 16;120(1):15–21. doi: 10.1016/0006-291x(84)91407-4. [DOI] [PubMed] [Google Scholar]
  27. Yoshida S., Akizuki M., Mimori T., Yamagata H., Inada S., Homma M. The precipitating antibody to an acidic nuclear protein antigen, the Jo-1, in connective tissue diseases. A marker for a subset of polymyositis with interstitial pulmonary fibrosis. Arthritis Rheum. 1983 May;26(5):604–611. doi: 10.1002/art.1780260505. [DOI] [PubMed] [Google Scholar]
  28. al-Janadi M., Smith C. D., Karsh J. Cyclophosphamide treatment of interstitial pulmonary fibrosis in polymyositis/dermatomyositis. J Rheumatol. 1989 Dec;16(12):1592–1596. [PubMed] [Google Scholar]
  29. von Mühlen C. A., Tan E. M. Autoantibodies in the diagnosis of systemic rheumatic diseases. Semin Arthritis Rheum. 1995 Apr;24(5):323–358. doi: 10.1016/s0049-0172(95)80004-2. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Neurology, Neurosurgery, and Psychiatry are provided here courtesy of BMJ Publishing Group

RESOURCES